Chinese investors lead another monster round into this early cancer detection company
Looking to detect cancer early through a simple blood test, Grail Inc. raised a $300 million from several Chinese investors on top of $1.2 billion in two earlier rounds over the past two years.
The Menlo Park company, which has been rumored to be planning a $500 million initial public offering in Hong Kong later this year, said the oversubscribed Series C round will help it develop and validate experimental products for early cancer detection.
A year ago, it bought Chinese blood diagnos tics company…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Ron Leuty Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | China Health | Health Management | Hong Kong Health | Men | Tics